16 results about "Slow release drug" patented technology

The present application relates to a kind of porous scaffold for repairing bone defect loaded with black phosphorus active oxygen elimination and slow-release drug and its preparation method;The scaffold includes the amino cation polymer grafted with the phenylboronic acid (PBA) and cyclodextrin (CD) that can eliminate active oxygen, black phosphorus nanosheet (BP) and scaffold material poly (lactic acid-glycolic acid) (PLGA).The porous scaffold loads a large number of black phosphorus nanosheet that can be hydrolyzed into bone repair nutrients, and the porous structure provides sufficient space for cell migration and growth, realizes the good repair of bone.Active oxygen elimination ability, can eliminate active oxygen in diabetic microenvironment.In addition, cyclodextrin can load a variety of drugs, such as osteogenic differentiation induction drug, and realize the slow release of drug.The porous scaffold has good biocompatibility, and the degradation product is harmless to human body, can be used for the tissue repair of bone defect, can be widely applied in the field of biological medicine and tissue engineering, and has been proved to have good repair ability in the diabetic rat skull defect model.

The invention is directed to pharmaceutical compositions for oral administration comprising deferiprone. In particular the invention is directed to a modified-release formulation in form of mini-tablets suitable for twice-a-day oral administration for the treatment of diseases which cause an overload of iron for example, thalassemia, sickle cell anemia, hemochromatosis, and myelodysplasia, or for the prevention and / or treatment of diseases which are caused by an overload of iron. The invention is also directed to methods of making said formulation.

This invention relates to an orally administrated nutritional supplement for the management of symptoms of irritable bowel syndrome (IBS) and related functional disorders. The composition includes:1) zinc-L-carnosine 60-100 mg per daily dose or an equivalent combination of zinc and L-carnosine providing 16?20 mg elemental Zn and 55-60 mg L-carnosine; 2) extract of Boswellia serrata resin with 25-35% total AKBA yielding 60-90 mg AKBA; 3) a probiotic blend 30-100 billion CFU that includes, at least, one strain from the genera Streptococcus, Bifidobacterium, and Lactobacillus. The active ingredients are incorporated into an acid-resistant or slow-release pharmaceutical form which limits their release in gastric pH and releases them when the pH is "greater than or equal to" 5.5, ensuring their integrity until they reach the intestine. The combination of the three above components strengthens the intestinal barrier, reduces intestinal inflammation, and restores the intestinal microbiota, providing comprehensive support to patients with IBS and related functional intestinal disorders.

The present application relates to a sustained-release pharmaceutical composition of GLP-1 receptor agonist and a preparation method thereof. The composition comprises 0.05-0.5 wt% active ingredient, 45-85 wt% sustained-release agent, and 15-55 wt% viscosity reducer, or comprises 0.05-0.5 wt% active ingredient and 45-99.95 wt% thermal sensitive sustained-release agent. The active ingredient is GLP-1 receptor agonist, the sustained-release agent is polyorthoester, and the viscosity reducer is preferably glycerate compound. The present application also provides a pharmaceutical combination product comprising the sustained-release pharmaceutical composition, and application of the composition in treating metabolic related diseases. The sustained-release pharmaceutical composition has significantly improved pharmacokinetic characteristics, can realize long-acting administration, improve patient compliance, and shows excellent effects in improving blood glucose control, promoting weight loss, and improving blood lipid level.

The present disclosure provides for methods of producing analgesia in a subject. In some cases, methods produce analgesia in a subject undergoing arthroscopic subacromial decompression surgery. The present disclosure also relates to improved sustained release drug delivery systems. In some cases, a composition comprises an active pharmaceutical agent; at least one of sucrose acetate isobutyrate and a polyorthoester; an organic solvent; and 2,6-dimethylaniline, wherein the 2,6-dimethylaniline is present at a level less than 500 ppm. In some cases, a composition comprises bupivacaine N-oxide at a level less than 1 wt %, based on weight of the composition. In some cases, a composition comprises metal present at a level less than 5 ppm. Dosage forms and methods are also provided.

The present disclosure relates to the field of ocular implants suitable for sustained release of drugs (e.g., water-soluble drugs) and use of the ocular implants for treatment of ocular conditions, including glaucoma.

Provided are a sustained-release pharmaceutical composition of a GLP-1 receptor agonist and a preparation method therefor. The composition contains 0.05 wt% to 0.5 wt% of an active ingredient, 45 wt% to 85 wt% of a sustained-release agent, and 15 wt% to 55 wt% of a viscosity-reducing agent, or contains 0.05 wt% to 0.5 wt% of an active ingredient, and 45 wt% to 99.95 wt% of a thermal sensitive sustained-release agent, wherein the active ingredient is a GLP-1 receptor agonist, the sustained-release agent is a polyorthoester, and the viscosity-reducing agent is preferably a glyceryl ester compound. Further provided are a drug-medical device combination product containing the sustained-release pharmaceutical composition, wherein the drug is the above-described sustained-release drug, and the medical device is a jet microneedle capable of injecting high-viscosity substances, and the use of the composition in the treatment of metabolism-related diseases. The sustained-release pharmaceutical composition has significantly improved pharmacokinetic characteristics, can realize long-acting administration, improves patient compliance, and exhibits good effects in improving blood glucose control, promoting weight loss, improving blood lipid levels, etc.

The application relates to the technical field of antibacterial patches, and particularly discloses an antibacterial slow-release patch, which comprises a skin-friendly and air-permeable layer arranged on the outer side and a slow-release drug layer arranged on the inner side of the skin-friendly and air-permeable layer, a sweat-absorbing substrate layer is arranged on the inner side of the slow-release drug layer, a back adhesive layer is arranged on the rear side of the sweat-absorbing substrate layer, a release paper layer is arranged on the rear side of the back adhesive layer, and a plurality of gel pieces are adhered to the back adhesive layer; the antibacterial slow-release patch is designed in a multilayer structure, can not only resist bacteria and inflammation and efficiently lock water, but also can reduce skin problems caused by sweat accumulation from multiple dimensions. On one hand, bacterial growth is inhibited to avoid inflammation caused by bacterial infection; on the other hand, the skin is kept dry to prevent the horny layer from being excessively hydrated, reduce the occurrence probability of skin diseases such as eczema and miliaria, and provide comprehensive protection for skin health, and the antibacterial slow-release patch is particularly suitable for scenes with more sweat such as sports and high temperature.

The invention relates to the technical field of biological medicine auxiliary instruments, and particularly discloses a sustained-release type anti-HPV vaginal packing gel carrier and an injector thereof, the gel carrier is mainly composed of two parts, one part is gel containing anti-HPV active ingredients, and the other part is a carrier for promoting the gel to adhere to the body. And a layer of water-soluble temperature control PVA film is sprayed between the carrier and the gel. Through pushing of the injector, the carrier expands in the vagina to play a role of the carrier, and meanwhile, the gel is uniformly and effectively attached to the vagina wall due to the fact that wrinkles on the vagina wall are opened through expansion, and the situation that the gel flows out along with changes of the body position of a patient or is diluted by secretions to lose the effective acting concentration to affect the acting effect is avoided. The effect of killing the HPV virus can be effectively achieved. The sponge can actively adsorb a mixture containing viruses and drugs, and the contact rate of the viruses and the drugs is greatly increased. In addition, the adsorption effect of the sponge can continuously capture newly-fallen viruses, and the sponge has the effect of slowly releasing drugs and better resists HPV viruses.

The application discloses a bone repair composite material with gelatin microspheres capable of releasing drugs and a preparation method thereof, and comprises the following steps: preparing a microfluid channel by 3D printing and performing surface modification on the microfluid channel by adopting tetramethyldisiloxane; adding gelatin into a phosphate buffer solution, dissolving, then adding antibiotics, stirring uniformly, and obtaining an aqueous phase; uniformly mixing mineral oil and a dispersing agent to obtain an oil phase; simultaneously feeding the aqueous phase and the oil phase into the modified microfluid channel to obtain drug-loaded gelatin microspheres; adding a crosslinking agent into the drug-loaded gelatin microspheres, freeze-drying, obtaining a drug-encapsulated gelatin drug packaging micro-particle carrier, and then mixing the drug-encapsulated gelatin drug packaging micro-particle carrier with calcium phosphate cement, and solidifying.

The present application provides the use of methylcatester for treating periodontitis. The present application also provides a method for preparing a sustained-release drug film containing methylcatester. The sustained-release drug film provided by the present application can inhibit the release of inflammatory factors, inhibit bacterial adhesion, and has a sustained-release time of up to the seventh day, has obvious effect on anti-periodontitis, and can effectively reduce the pathological changes of periodontal tissue.

The present invention relates to bioorthoscopic biodegradable hydrogels for sustained-release drug delivery, methods for preparing bioorthoscopic biodegradable hydrogels, their use as implantable materials in the treatment of diseases, kits for preparing hydrogels in situ at the treatment site, and methods of treatment using hydrogels or kits, such as for treating eye diseases.

The utility model discloses a three -month paste with slow -release function belongs to the plaster of traditional chinese medicine technical field, three -month paste with slow -release function still includes the glue layer 12 of fixed connection on the upper end of cotton gauze layer 11, the inside of glue layer 12 is inlayed a pair of heat dissipation silica gel 13, two heat dissipation silica gel 13 and cover -like slow -release membrane 17 between inlayed snap ring 14, the outer circumference of snap ring 14 is fixedly connected with glue layer 12, and the lower end of two heat dissipation silica gel 13 is embedded in the inside of cotton gauze layer 11, through setting heat dissipation silica gel 13, further clamping hold snap ring 14, can conduct heat to outside while assisting clamping plaster 15, can be embedded glue layer 12 and cotton gauze layer 11 simultaneously, the connection of stable glue layer 12 and cotton gauze layer 11 prevents misplacement, improves the stability of three -month paste while increasing the cooling function, is more favorable to the absorption of slow -release medicine.

The application discloses a solid medicament releasing device, a solid medicament delivery pipe column and a use method, and the releasing device comprises a solid medicament containing cylinder, a blocking mechanism and a locking and unlocking mechanism; the lower end of the solid medicament containing cylinder is of an open structure, the lower end of the solid medicament containing cylinder is connected with the blocking mechanism, the lower end of the blocking mechanism is connected with the locking and unlocking mechanism, and the locking and unlocking mechanism controls the opening of the blocking mechanism. The solid medicament releasing device adopts a pressing mode to open, precise control of a releasing time can be realized, and the releasing time is more reliable; the solid medicament releasing device can be provided with multiple stages, and the effective period of the medicament is prolonged; when the solid anticorrosive slow-release medicament particles are delivered, the solid medicament releasing device can realize full wellbore anticorrosion, the protection is more comprehensive, long-acting anticorrosion of the oil well is realized, the production cycle of the oil well is prolonged, and the production rate of the oil well is improved.

This invention discloses a method for preparing a photothermal controlled-release hydrogel contact lens material. The method involves chemically bonding ganciclovir with hydroxypropyltrimethylammonium chloride chitosan, then adding methacrylic anhydride to introduce double bonds. The resulting product is used as a crosslinking agent to crosslink and copolymerize with hydroxyethyl methacrylate (MXene) nanosheets to prepare the hydrogel material. The prepared photothermal controlled-release hydrogel contact lens material can bond drugs to the polymer chains of the hydrogel contact lens for drug loading, avoiding drug loss due to tear rinsing, thereby improving drug storage stability. Furthermore, it can be modulated with near-infrared light to generate a photothermal effect, raising the hydrogel temperature and triggering the breakage of thermosensitive azo bonds, releasing the drug into the contact lens matrix. When the lens is worn, the drug can be slowly released from the contact lens into the eye, potentially making it a multifunctional contact lens material for treating eye diseases.